These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 22465747)

  • 1. Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis.
    Shargh VH; Jaafari MR; Khamesipour A; Jaafari I; Jalali SA; Abbasi A; Badiee A
    Vaccine; 2012 Jun; 30(26):3957-64. PubMed ID: 22465747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis.
    Heravi Shargh V; Jaafari MR; Khamesipour A; Jalali SA; Firouzmand H; Abbasi A; Badiee A
    Parasitol Res; 2012 Jul; 111(1):105-14. PubMed ID: 22223037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA).
    Firouzmand H; Badiee A; Khamesipour A; Heravi Shargh V; Alavizadeh SH; Abbasi A; Jaafari MR
    Acta Trop; 2013 Dec; 128(3):528-35. PubMed ID: 23916506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEGylation of cationic liposomes encapsulating soluble Leishmania antigens reduces the adjuvant efficacy of liposomes in murine model.
    Naseri H; Eskandari F; Jaafari MR; Khamesipour A; Abbasi A; Badiee A
    Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28921566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of in vivo Adjuvanticity of Liposomal PO CpG ODN with Liposomal PS CpG ODN: Soluble Leishmania Antigens as a Model.
    Golali E; Jaafari MR; Khamesipour A; Abbasi A; Saberi Z; Badiee A
    Iran J Basic Med Sci; 2012 Sep; 15(5):1032-45. PubMed ID: 23493437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins.
    Tafaghodi M; Eskandari M; Kharazizadeh M; Khamesipour A; Jaafari MR
    Trop Biomed; 2010 Dec; 27(3):639-50. PubMed ID: 21399606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
    Ravindran R; Maji M; Ali N
    Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoliposomes containing Soluble Leishmania Antigens (SLA) as a novel antigen delivery system in murine model of leishmaniasis.
    Eskandari F; Talesh GA; Parooie M; Jaafari MR; Khamesipour A; Saberi Z; Abbasi A; Badiee A
    Exp Parasitol; 2014 Nov; 146():78-86. PubMed ID: 25246326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alginate microspheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN induced partial protection and enhanced immune response against murine model of leishmaniasis.
    Tafaghodi M; Eskandari M; Khamesipour A; Jaafari MR
    Exp Parasitol; 2011 Oct; 129(2):107-14. PubMed ID: 21767536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.
    Jaafari MR; Badiee A; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
    Vaccine; 2007 Aug; 25(32):6107-17. PubMed ID: 17629372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cationic liposomes formulated with a novel whole Leishmania lysate (WLL) as a vaccine for leishmaniasis in murine model.
    Jafari I; Heravi Shargh V; Shahryari M; Abbasi A; Jaafari MR; Khamesipour A; Badiee A
    Immunobiology; 2018; 223(6-7):493-500. PubMed ID: 29317110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cationic Immune Stimulating Complexes Containing Soluble Leishmania Antigens: Preparation, Characterization and in Vivo Immune Response Evaluation.
    Mehravaran A; Jaafari MR; Jalali SA; Khamesipour A; Tafaghodi M; Hojatizade M; Abbasi A; Badiee A
    Iran J Immunol; 2015 Dec; 12(4):274-87. PubMed ID: 26714419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of MPL and imiquimod adjuvants in enhancement of immune response and protection in BALB/c mice immunized with soluble Leishmania antigen (SLA) encapsulated in nanoliposome.
    Emami T; Rezayat SM; Khamesipour A; Madani R; Habibi G; Hojatizade M; Jaafari MR
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):324-333. PubMed ID: 29607698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis.
    Ferreira JH; Gentil LG; Dias SS; Fedeli CE; Katz S; Barbiéri CL
    Vaccine; 2008 Jan; 26(5):677-85. PubMed ID: 18160187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.
    Badiee A; Jaafari MR; Khamesipour A
    Exp Parasitol; 2007 Feb; 115(2):127-34. PubMed ID: 16979165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63).
    Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
    Exp Parasitol; 2009 Apr; 121(4):362-9. PubMed ID: 19211022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
    Daifalla NS; Bayih AG; Gedamu L
    Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis.
    Agallou M; Margaroni M; Karagouni E
    Vaccine; 2011 Jul; 29(31):5053-64. PubMed ID: 21569815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN.
    Tafaghodi M; Khamesipour A; Jaafari MR
    Parasitol Res; 2011 May; 108(5):1265-73. PubMed ID: 21125294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.